ArriVent Reports 44.8% Response Rate for ARR-217 in Phase 1 CRC Data
ArriVent BioPharma reported initial Phase 1 data showing a 44.8% objective response rate among pretreated colorectal cancer patients at the 6 mg/kg dose.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.